-
-
-
-
-
-
-
Zentalis Pharmaceuticals, Inc. (ZNTL) Tops Q2 EPS by 17c
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update
-
-
-
-
-
-
-
Zentalis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Update
-
1,199,642 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

